Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
To evaluate Rani's Pill technology for the oral delivery of FVIII therapy for hemophilia A
December 5, 2017
By: Kristin Brooks
Managing Editor, Contract Pharma
Shire plc and Rani Therapeutics have entered a collaboration to exclusively conduct research using the Rani Pill technology for the oral delivery of factor VIII (FVIII) therapy for hemophilia A. Shire has an exclusive option to negotiate a license to develop and commercialize the technology for delivery of FVIII therapy following feasibility studies. Shire has also made an equity investment in Rani Therapeutics. Rani Therapeutics has developed a new approach for the oral delivery of large molecules, including peptides, proteins, and antibodies, using the Rani Pill, a capsule that delivers an intestinal injection without exposing medication to digestive enzymes. Once the capsule is consumed, it stays protected until it enters the small intestine and delivers medication into the intestinal wall where delivery is expected to be pain free. “Shire is proud to partner with Rani Therapeutics to pioneer the investigation of oral delivery of factor therapy for the hemophilia community,” said Fritz Scheiflinger, head of Global Research, Shire. “With Shire’s in-depth scientific expertise and leadership position in hemophilia and Rani Therapeutics’ deep experience in engineering and material science, we are excited by the potential of this partnership to reduce the chronic burden of hemophilia on patients’ everyday lives by researching an oral option to deliver FVIII to patients. We strive to provide hemophilia patients with innovative therapies that are effective and do not expose patients to additional risks.” “We are very pleased to collaborate with Shire on the development of oral FVIII delivery,” said Mir Imran, chairman and chief executive officer, Rani Therapeutics. “With this technology, though early in development in hemophilia, we hope to improve compliance, quality of life and outcomes for patients with hemophilia by offering a painless and more convenient oral delivery.” <!– /* Font Definitions */ @font-face {font-family:Arial; panose-1:2 11 6 4 2 2 2 2 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-536859905 -1073711037 9 0 511 0;} @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:1; mso-generic-font-family:roman; mso-font-format:other; mso-font-pitch:variable; mso-font-signature:0 0 0 0 0 0;} @font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-536870145 1073786111 1 0 415 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0in; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin;} p {mso-style-priority:99; mso-margin-top-alt:auto; margin-right:0in; mso-margin-bottom-alt:auto; margin-left:0in; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin;} span.apple-converted-space {mso-style-name:apple-converted-space; mso-style-unhide:no;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;} @page WordSection1 {size:8.5in 11.0in; margin:1.0in 1.0in 1.0in 1.0in; mso-header-margin:.5in; mso-footer-margin:.5in; mso-paper-source:0;} div.WordSection1 {page:WordSection1;} –Shire plc and Rani Therapeutics have entered a collaboration to exclusively conduct research using the Rani Pill technology for the oral delivery of factor VIII (FVIII) therapy for hemophilia A. Shire has an exclusive option to negotiate a license to develop and commercialize the technology for delivery of FVIII therapy following feasibility studies. Shire has also made an equity investment in Rani Therapeutics.Rani Therapeutics has developed a new approach for the oral delivery of large molecules, including peptides, proteins, and antibodies, using the Rani Pill, a capsule that delivers an intestinal injection without exposing medication to digestive enzymes. Once the capsule is consumed, it stays protected until it enters the small intestine and delivers medication into the intestinal wall where delivery is expected to be pain free. “Shire is proud to partner with Rani Therapeutics to pioneer the investigation of oral delivery of factor therapy for the hemophilia community,” said Fritz Scheiflinger, head of Global Research, Shire. “With Shire’s in-depth scientific expertise and leadership position in hemophilia and Rani Therapeutics’ deep experience in engineering and material science, we are excited by the potential of this partnership to reduce the chronic burden of hemophilia on patients’ everyday lives by researching an oral option to deliver FVIII to patients. We strive to provide hemophilia patients with innovative therapies that are effective and do not expose patients to additional risks.”“We are very pleased to collaborate with Shire on the development of oral FVIII delivery,” said Mir Imran, chairman and chief executive officer, Rani Therapeutics. “With this technology, though early in development in hemophilia, we hope to improve compliance, quality of life and outcomes for patients with hemophilia by offering a painless and more convenient oral delivery.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !